An updated patent review of Mcl-1 inhibitors (2020–2022)

References

• Moldoveanu T, Follis AV, Kriwacki RW, et al. Many players in BCL-2 family affairs. Trends Biochem Sci. 2014 Mar;39(3):101–111. doi:10.1016/j.tibs.2013.12.006. Epub 2014 Feb 3. PMID: 24503222; PMCID: PMC4005919.
   PubMed Web of Science ®Google Scholar
• Gores GJ, Kaufmann SH. Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev. 26(4): 305–311. 2012 Feb 15. 10.1101/gad.186189.111 PMID: 22345513; PMCID: PMC3289878.
   PubMed Web of Science ®Google Scholar
• Hird AW, Tron AE. Recent advances in the development of Mcl-1 inhibitors for cancer therapy. Pharmacol Ther. 2019 Jun;198:59–67. doi:10.1016/j.pharmthera.2019.02.007. Epub 2019 Feb 18. PMID: 30790641.
   PubMed Web of Science ®Google Scholar
• Shahar N, Larisch S. Inhibiting the inhibitors: targeting anti-apoptotic proteins in cancer and therapy resistance. Drug Resist Updat. 2020 Sep;52:100712. doi:10.1016/j.drup.2020.100712. Epub 2020 Jun 20. PMID: 32599435.
   PubMed Web of Science ®Google Scholar
• Czabotar PE, Lee EF, van Delft MF, et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci U S A. 104(15). 6217–6222. 2007 Apr 10. 10.1073/pnas.0701297104. Epub 2007 Mar 27. PMID: 17389404; PMCID: PMC1851040.
   PubMed Web of Science ®Google Scholar
• Stewart ML, Fire E, Keating AE, et al. The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol. 2010 Aug;6(8):595–601. doi:10.1038/nchembio.391. Epub 2010 Jun 20. PMID: 20562877; PMCID: PMC3033224.
   PubMed Web of Science ®Google Scholar
• Denis C, Sopková-de Oliveira Santos J, Bureau R, et al. Hot-spots of Mcl-1 protein. J Med Chem. 63(3). 928–943. 2020 Feb 13. 10.1021/acs.jmedchem.9b00983. Epub 2019 Oct 16. PMID: 31580668.
   PubMed Web of Science ®Google Scholar
• Negi A, Murphy PV. Development of Mcl-1 inhibitors for cancer therapy. Eur J Med Chem. 2021 Jan 15; 210 : 113038. 10.1016/j.ejmech.2020.113038. Epub 2020 Nov 24. PMID: 33333396.
   PubMed Web of Science ®Google Scholar
• Wendt MD, Shen W, Dickman DA, et al. Preparation of biphenyl carboxylic acid derivatives as apoptosis promoters. 2007. WO2007/008627
   Google Scholar
• Bruncko M, Wang L, Sheppard GS, et al. Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity. J Med Chem. 2015 Mar 12;58(5):2180–2194. DOI:10.1021/jm501258m. Epub 2015 Feb 26. Erratum in: J Med Chem. 2015 May 14;58(9):4089. PMID: 25679114.
   PubMed Web of Science ®Google Scholar
• Kotschy A, Szlavik Z, Murray J, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016 Oct 27;538(7626):477–482. doi:10.1038/nature19830. Epub 2016 Oct 19. PMID: 27760111.
   PubMed Web of Science ®Google Scholar
• Szlávik Z, Ondi L, Csékei M, et al. Structure-guided discovery of a selective Mcl-1 inhibitor with cellular activity. J Med Chem. 62(15). 6913–6924. 2019 Aug 8. 10.1021/acs.jmedchem.9b00134. Epub 2019 Jul 24. PMID: 31339316.
   PubMed Web of Science ®Google Scholar
• Szlavik Z, Csekei M, Paczal A, et al. Discovery of S64315, a potent and selective Mcl-1 inhibitor. J Med Chem. 63(22). 13762–13795. 2020 Nov 25. 10.1021/acs.jmedchem.0c01234. Epub 2020 Nov 4. PMID: 33146521.
   PubMed Web of Science ®Google Scholar
• Caenepeel S, Brown SP, Belmontes B, et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 2018 Dec;8(12):1582–1597. doi:10.1158/2159-8290.CD-18-0387. Epub 2018 Sep 25. Erratum in: Cancer Discov. 2019 Jul;9(7):980. PMID: 30254093.
   PubMed Web of Science ®Google Scholar
• Sean C, Rex K, Brian B, et al. Abstract 6218: discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor. Cancer Res. 15 Aug 2020;80(16_Supplement):6218. DOI:10.1158/1538-7445.AM2020-6218
   Web of Science ®Google Scholar
• Tron AE, Belmonte MA, Adam A, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018 Dec 17;9(1):5341. doi:10.1038/s41467-018-07551-w. PMID: 30559424; PMCID: PMC6297231.
   PubMedGoogle Scholar
• Lee T, Christov PP, Shaw S, et al. J Med Chem. 2019 Apr 25; 62(8): 3971–3988. doi: 10.1021/acs.jmedchem.8b01991. Epub 2019 Apr 16. PMID: 30929420.
   PubMed Web of Science ®Google Scholar
• Fu Z, Li S, Han S, et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022 Mar 22;7(1):93. doi:10.1038/s41392-022-00947-7. PMID: 35318309; PMCID: PMC8941077.
   PubMed Web of Science ®Google Scholar
• Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022 Mar;21(3):181–200. doi:10.1038/s41573-021-00371-6. Epub 2022 Jan 18. PMID: 35042991; PMCID: PMC8765495.
   PubMed Web of Science ®Google Scholar
• Chen L, Fletcher S. Mcl-1 inhibitors: a patent review. Expert Opin Ther Pat. 2017 Feb;27(2):163–178. doi:10.1080/13543776.2017.1249848. Epub 2016 Nov 17. PMID: 27744724.
   PubMed Web of Science ®Google Scholar
• Fletcher S. MCL-1 inhibitors – where are we now (2019)? Expert Opin Ther Patents. 2019 Nov;29(11):909–919. doi:10.1080/13543776.2019.1672661. Epub 2019 Oct 14. PMID: 31566022.
   PubMed Web of Science ®Google Scholar
• Brown SP, Li Y, Lizarzaburu ME, et al. Tetrahydronaphthalene derivatives that inhibit MCL-1 protein. WO2016/033486. 2016.
   Google Scholar
• Brown SP, Bedke DK, Degraffenreid MR, et al. Preparation of spironaphthaleneoxathiadiazatetracyclopentacosatetraenonedioxide derivatives and analogs for use as MCL-1 protein inhibitors. WO2017/147410. 2017.
   Google Scholar
• Harrington PE, Ashton K, Brown SP, et al. Macrocyclic compounds that inhibit Mcl-1 protein and their preparation. 2018;WO2018/183418.
   Google Scholar
• Brown SP, Harrington PE, Lanman BA, et al. Preparation of macrocyclic compounds that inhibit Mcl-1 protein. 2019;WO2019/046150.
   Google Scholar
• Brown SP, Lanman BA, Li K, et al. Preparation of macrocyclic compounds that inhibit Mcl-1 protein. WO2019/036575. 2019.
   Google Scholar
• Rescourio G, Buenrostro AG, Brown SP, et al. Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere MCL-1 protein antagonists. WO2019/173181. 2019.
   Google Scholar
• Kelly R, Kennedy M, La S. Formulations and dosages for administering a compound that inhibits Mcl1 protein. 2021;WO2021/021259.
   Google Scholar
• Achmatowicz M, Cui S, Hwang T, et al. Preparation of Mcl-1 inhibiting compound by methylation in the presence of water and pharmaceutical formulation comprising the same. 2021;WO2021/202452.
   Google Scholar
• Smith A, Huang L. Synthesis of vinylic protected alcohol intermediates useful in the synthesis of macrocyclic Mcl-1 inhibitors via reductive alkylation. 2021;WO2021/225823.
   Google Scholar
• Langille N, Tedrow J, Truong J, et al. Synthesis of sulfonamide intermediates useful in the synthesis of macrocyclic Mcl-1 inhibitors. 2021;WO2021/225833.
   Google Scholar
• Farrell R, Tedrow J. Synthesis of vinylic alcohol intermediates useful in the synthesis of macrocyclic Mcl-1 inhibitors via addition reaction, especially Grignard addition. 2021;WO2021/225835.
   Google Scholar
• Smith A, Corbett M, Langille N, et al. Synthesis of vinyl cyclobutyl intermediates useful in the synthesis of macrocyclic Mcl-1 inhibitors. 2021;WO2021/226009.
   Google Scholar
• Smith A, Tedrow J, St-Pierre G, et al. Synthesis of macrocyclic Mcl-1 inhibitor intermediates via ring-closing metathesis. 2021;WO2021/226168.
   Google Scholar
• Beaver M, Dennis J, Dornan P, et al. Diol desymmetrization by nucleophilic aromatic substitution. 2022;WO2022/051317.
   Google Scholar
• Baucom K, Corbett M, Cui S, et al. Enantioselective preparation of vinyl cyclobutyl intermediates useful in the synthesis of Mcl-1 inhibitors. 2022;WO2022/115400.
   Google Scholar
• Chu H, Guerrero JA, Hurtley AE, et al. Preparation of macrocyclic compounds as MCL1 inhibitors. 2021. WO2021/096860
   Google Scholar
• Rescourio G, Gonzalez AZ, Jabri S, et al. Discovery and in vivo evaluation of macrocyclic Mcl-1 inhibitors featuring an α-hydroxy phenylacetic acid pharmacophore or bioisostere. J Med Chem. 62(22). 10258–10271. 2019 Nov 27. 10.1021/acs.jmedchem.9b01310. Epub 2019 Nov 18. PMID: 31736296.
   PubMed Web of Science ®Google Scholar
• Tang G, Li D, Li L, et al. Preparation of macrocyclic fused pyrazoles as Mcl-1 inhibitors. 2020;WO2020/151738.
   Google Scholar
• Chen J, Zhou Y, Tang G, et al. Preparation of macrocyclic spiro ethers as Mcl-1 inhibitors. 2020;WO2020/147802.
   Google Scholar
• Zhuo J. 2-((5-(phenyl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-3-(phenyl)propanoic acid derivatives and related compounds as MCL-1 enzyme inhibitors for treating cancer. 2020;WO2020/123994.
   Google Scholar
• Zhuo J, Leal R, Shetty R, et al. Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein. 2020;WO2020/097577.
   Google Scholar
• Kotschy A, Szlávik Z, Csékei M, et al. New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them. 2015;WO2015/097123.
   Google Scholar
• De Baets E, Auvray J, Lynch M, et al. New crystalline forms of a MCL-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them. 2020;WO2020/115183.
   Google Scholar
• Rombouts F, Peschiulli A. Macrocyclic indole-naphthalene inhibitors of MCL-1 and their preparation, pharmaceutical compositions and use in the treatment of cancer. 2020;WO2020/254471.
   Google Scholar
• Rombouts F, Reuillon T, Peschiulli A, et al. Preparation of macrocyclic indole derivatives as inhibitors of MCL-1 for the treatment and prophylaxis of cancer and other diseases. WO2021/165370. 2021.
   Google Scholar
• Rombouts F, De Boeck BCAG. Macrocyclic indole derivatives as MCL-1 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. 2021;WO2021/099579.
   Google Scholar
• Rombouts F, De Boeck BCAG. Macrocyclic sulfonyl derivatives as MCL-1 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. 2021;WO2021/099580.
   Google Scholar
• Rombouts F, Diels GSM, Jerhaoui S, et al. Macrocyclic spirocycle derivatives as MCL-1 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. 2021;WO2021/005043.
   Google Scholar
• O’boyle BM, Baker-Tripp EL, Reeves CM, et al. The structure and immune regulatory implications of the ubiquitin-like tandem domain within an avian 2’-5’ oligoadenylate synthetase-like protein. Front Immunol. 2021;12:WO2021/067827. doi:10.3389/fimmu.2021.794664
   PubMed Web of Science ®Google Scholar
• Baker-Tripp EL, Reeves CM, M SB, et al. Preparation of isothiazolopyridine derivatives as MCL1 inhibitors and uses thereof. 2022;WO2022/216946.
   Google Scholar
• Zhang J, Huang PQ, Bunker KD, et al. Macrocyclic compounds as Mcl-1 inhibitors and their preparation. 2020;WO2020/185606.
   Google Scholar
• Zhang J, Huang PQ, Bunker KD, et al. Preparation of macrocyclic compounds as Mcl-1 inhibitors useful for treatment of cancer. 2021;WO2021/126316.
   Google Scholar
• Zhang G, Fei H, Zhang X, et al. Preparation of indole containing macrocyclic compound as MCL-1 inhibitor. 2020;WO2020/063792.
   Google Scholar
• You Q, Jiang Z, Zhu P, et al. High-efficiency 3,5-dimethyl-4-sulfone-1H-pyrrole compound, and its application as Mcl-1 inhibitor. 2022;WO2022/111202.
   Google Scholar
• Fu Z, Li S, Han S, et al. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022 Mar 22;7(1):93. doi:10.1038/s41392-022-00947-7 PMID: 35318309; PMCID: PMC8941077.
   PubMed Web of Science ®Google Scholar
• Tarantino P, Carmagnani Pestana R, Corti C, et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022 Mar;72(2):165–182. doi:10.3322/caac.21705. Epub 2021 Nov 12. PMID: 34767258.
   PubMed Web of Science ®Google Scholar
• Burger M, Chanrion M, Colland F, et al. Preparation of peptides and myeloid cell leukemia-1 inhibitor antibody-drug conjugates as antitumor agents. 2020;WO2020/236817.
   Google Scholar
• Burger M, Chanrion M, Colland F, et al. Preparation of peptides and myeloid cell leukemia-1 inhibitor antibody-drug conjugates as antitumor agents. 2020;WO2020/236825.
   Google Scholar
• Thomas RL, Roberts DJ, Kubli DA, et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 27(12): 1365–1377. 2013 Jun 15. 10.1101/gad.215871.113 PMID: 23788623; PMCID: PMC3701192.
   PubMed Web of Science ®Google Scholar
• Wang X, Bathina M, Lynch J, et al. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 27(12). 1351–1364. 2013 Jun 15. 10.1101/gad.215855.113. PMID: 23788622; PMCID: PMC3701191.
   PubMed Web of Science ®Google Scholar
• Khan S, Zhang X, Lv D, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019 Dec;25(12):1938–1947. doi:10.1038/s41591-019-0668-z. Epub 2019 Dec 2. PMID: 31792461; PMCID: PMC6898785.
   PubMed Web of Science ®Google Scholar
• Cottens S, Drewniak-Switalska M, Kaczanowska K, et al. Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target MCL protein. 2022;WO2022/253713.
   Google Scholar
• Voisin-Chiret A-S, Kieffer C, Guedeney G, et al. BCL-2 family proteins modulating compounds for cancer treatment. 2021;WO2021/180966.
   Google Scholar
• Zhang Z, Wang Z. Preparation of thio/oxo-naphthalimide compound as BCL-2 and MCL-1 inhibitors. CN107382862. 2017.
   Google Scholar
• Jain A, Liu R, Ramani B, et al. Probing cellular protein complexes using single-molecule pull-down. Nature. 2011 May 26;473(7348):484–488. doi:10.1038/nature10016. PMID: 21614075; PMCID: PMC3103084.
   PubMed Web of Science ®Google Scholar
• Lee HW, Kyung T, Yoo J, et al. Real-time single-molecule co-immunoprecipitation analyses reveal cancer-specific Ras signalling dynamics. Nat Commun. 2013;4:1505. doi:10.1038/ncomms2507 PMID: 23422673; PMCID: PMC3586730.
   PubMed Web of Science ®Google Scholar